Skp2-IN-4

Skp2-IN-4 is an Skp2 inhibitor with a IC50 of 0.38 μM for Skp2-Cks1 binding. Skp2-IN-4 improves anti-tumor activity, inhibits the proliferation and induces S phase arrest by targeting Skp2. Skp2-IN-4 significantly enhances Cisplatin (HY-17394) chemosensitivity by suppressing the tumor cell stemness in NCl-H1299 xenograft mice model, promising for lung cancer and esophageal cancer research[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; DNA/RNA Synthesis; E1/E2/E3 Enzyme

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Field of Research

Cancer

Purity

98.02

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CN(CC1=CC=C(C#N)C=C1)C2=NC(C3=CC=CC=C3)=C(C4=CC=NC=C4)N=C2

Molecular Formula

C24H19N5

Molecular Weight

377.44

References & Citations

[1]Hu K, et al. Molecular hybridization strategy - discovery of 2,3-diarylpyrazine derivatives as potent Skp2 inhibitors with improved anti-tumor activity and enhanced cisplatin sensitivity. Eur J Med Chem. 2025 Oct 5; 295:117788.